Review

Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

*Author for correspondence: Tel.: +39 063 015 6265; Fax: +39 063 015 7023;

E-mail Address: gianluca.ianiro@hotmail.it

Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy

Search for more papers by this author

Jonathan P Segal

Department of Gastroenterology, St Mary’s Hospital, London, UK

Search for more papers by this author

Benjamin H Mullish

https://orcid.org/0000-0001-6300-3100

Division of Digestive Diseases, Department of Metabolism, Digestion & Reproduction, Faculty of Medicine, Imperial College London, London, UK

Search for more papers by this author

Mohammed N Quraishi

University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK

Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for more papers by this author

Serena Porcari

Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy

Search for more papers by this author

Ginevra Fabiani

Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy

Search for more papers by this author

Antonio Gasbarrini

Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy

Search for more papers by this author

Giovanni Cammarota

Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy

Search for more papers by this author

Published Online:21 Sep 2020https://doi.org/10.2217/fmb-2020-0061

View article

Abstract

Fecal microbiota transplantation (FMT) is the infusion of feces from a healthy donor into the gut of a recipient to treat a dysbiosis-related disease. FMT has been proven to be a safe and effective treatment for Clostridioides difficile infection, but increasing evidence supports the role of FMT in other gastrointestinal and extraintestinal diseases. The aim of this review is to paint the landscape of current evidence of FMT in different fields of application (including irritable bowel syndrome, inflammatory bowel disease, liver disorders, decolonization of multidrug-resistant bacteria, metabolic disorders and neurological disorders), as well as to discuss the current regulatory scenario of FMT, and hypothesize future directions of FMT.

Keywords:

References

1. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am. J. Gastroenterol. 107(11), 1755–1756 (2012).Crossref, Medline, Google Scholar
2. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38(6), 475–483 (2004).Crossref, Medline, Google Scholar
3. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44(5), 854–859 (1958).Medline, CAS, Google Scholar
4. Ianiro G, Maida M, Burisch J et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol. J. 6(8), 1232–1244 (2018).Crossref, Medline, Google Scholar
5. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4), 913–6.e7 (2012).Crossref, Medline, CAS, Google Scholar
6. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 36(6), 503–516 (2012).Crossref, Medline, CAS, Google Scholar
7. Cammarota G, Ianiro G, Kelly CR et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68(12), 2111–2121 (2019).Crossref, Medline, CAS, Google Scholar
8. Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66(4), 569–580 (2017).Crossref, Medline, Google Scholar
9. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am. J. Gastroenterol. 108(2), 177–185 (2013).Crossref, Medline, Google Scholar
10. Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108(10), 1620–1630 (2013).Crossref, Medline, CAS, Google Scholar
11. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145(5), 946–953 (2013).Crossref, Medline, Google Scholar
12. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29(1), 79–84 (2013).Crossref, Medline, Google Scholar
13. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107(5), 761–767 (2012).Crossref, Medline, Google Scholar
14. Ianiro G, Masucci L, Quaranta G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment. Pharmacol. Ther. 48(2), 152–159 (2018).Crossref, Medline, CAS, Google Scholar
15. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9(2), 88–96 (2011).Crossref, Medline, Google Scholar
16. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 95(11), 3283–3285 (2000).Medline, CAS, Google Scholar
17. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. J. Clin. Gastroenterol. 45(Suppl.), S159–S167 (2011).Crossref, Medline, Google Scholar
18. Bibbò S, Lopetuso LR, Ianiro G, Rienzo Di T, Gasbarrini A, Cammarota G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J. Immunol. Res. 2014, 462740 (2014).Crossref, Medline, Google Scholar
19. Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile Infection following fecal microbiota transplantation. mBio 7(6), e01965–16 (2016).Crossref, Medline, Google Scholar
20. Zuo T, Wong SH, Cheung CP et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 9(1), 3663 (2018).Crossref, Medline, Google Scholar
21. Weingarden AR, Dosa PI, DeWinter E et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth. PLoS ONE 11(1), e0147210 (2016).Crossref, Medline, Google Scholar
22. Quraishi MN, Widlak M, Bhala N et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment. Pharmacol. Ther. 46(5), 479–493 (2017).Crossref, Medline, CAS, Google Scholar
23. Hvas CL, Dahl Jørgensen SM, Jørgensen SP et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 156(5), 1324–1332.e3 (2019).Crossref, Medline, Google Scholar
24. Fischer M, Sipe B, Cheng YW et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 8(3), 289–302 (2017).Crossref, Medline, CAS, Google Scholar
25. Ianiro G, Valerio L, Masucci L et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin. Microbiol. Infect. 23(5), 337.e1–337.e3 (2017).Crossref, CAS, Google Scholar
26. Ianiro G, Murri R, Sciumè GD et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann. Intern. Med. 171(10), 695–702 (2019).Crossref, Medline, Google Scholar
27. Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for clostridium difficile infection after starting a program to transplant fecal microbiota. Ann. Intern. Med. 163(6), 487–488 (2015).Crossref, Medline, Google Scholar
28. Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(1), 102–109.e6 (2015).Crossref, Medline, Google Scholar
29. ossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149(1), 110–118.e4 (2015).Crossref, Medline, Google Scholar
30. Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075), 1218–1228 (2017).Crossref, Medline, Google Scholar
31. Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321(2), 156–164 (2019).Crossref, Medline, Google Scholar
32. Paramsothy S, Paramsothy R, Rubin DT et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J. Crohns Colitis. 11(10), 1180–1199 (2017).Crossref, Medline, Google Scholar
33. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1), 85–e15 (2014).Crossref, Medline, CAS, Google Scholar
34. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699–710 (2013).Crossref, Medline, CAS, Google Scholar
35. Sokol H, Landman C, Seksik P et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome 8(1), 12 (2020).Crossref, Medline, Google Scholar
36. Segal JP, Oke S, Hold GL, Clark SK, Faiz OD, Hart AL. Systematic review: ileoanal pouch microbiota in health and disease. Aliment. Pharmacol. Ther. 47(4), 466–477 (2018).Crossref, Medline, CAS, Google Scholar
37. Segal JP, Ding NS, Worley G et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm Aliment. Pharmacol. Ther. 45(5), 581–592 (2017).CAS, Google Scholar
38. Landy J, Walker AW, Li JV et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci. Rep. 5, 12955 (2015).Crossref, Medline, CAS, Google Scholar
39. Herfarth H, Barnes EL, Long MD et al. Combined endoscopic and oral fecal microbiota transplantation in patients with antibiotic-dependent pouchitis: low clinical efficacy due to low donor microbial engraftment. Inflamm. Intest. Dis. 4(1), 1–6 (2019).Crossref, Medline, Google Scholar
40. Nishida A, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: a case series. Clin. Case Rep. 7(4), 782–788 (2019).Crossref, Medline, Google Scholar
41. Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal microbiota transfer in patients with chronic antibiotic-refractory pouchitis. Am. J. Gastroenterol. 111(3), 441–443 (2016).Crossref, Medline, Google Scholar
42. El-Salhy M. Nutritional management of gastrointestinal diseases and disorders. Nutrients 11(12), 3013 (2019).Crossref, Google Scholar
43. Xu D, Chen VL, Steiner CA et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol. 114(7), 1043–1050 (2019).Crossref, Medline, Google Scholar
44. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 50(3), 240–248 (2019).Crossref, Medline, Google Scholar
45. Halkjær SI, Christensen AH, Lo BZS et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 67(12), 2107–2115 (2018).Crossref, Medline, CAS, Google Scholar
46. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 69(5), 859–867 (2020).Crossref, Medline, CAS, Google Scholar
47. Rosshart SP, Vassallo BG, Angeletti D et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171(5), 1015–1028.e13 (2017).Crossref, Medline, CAS, Google Scholar
48. Wong SH, Zhao L, Zhang X et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153(6), 1621–1633.e6 (2017).Crossref, Medline, Google Scholar
49. Cao H, Xu M, Dong W et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int. J. Cancer 140(11), 2545–2556 (2017).Crossref, Medline, CAS, Google Scholar
50. Ma C, Han M, Heinrich B et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360(6391), eaan5931 (2018).Crossref, Medline, Google Scholar
51. Pushalkar S, Hundeyin M, Daley D et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8(4), 403–416 (2018).Crossref, Medline, CAS, Google Scholar
52. Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371), 97–103 (2018).Crossref, Medline, CAS, Google Scholar
53. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).Crossref, Medline, CAS, Google Scholar
54. Wang Y, Wiesnoski DH, Helmink BA et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24(12), 1804–1808 (2018).Crossref, Medline, CAS, Google Scholar
55. Pinato DJ, Howlett S, Ottaviani D et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5(12), 1774–1778 (2019).Crossref, Medline, Google Scholar
56. Tacconelli E, Mazzaferri F, de Smet AM et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. Clin. Microbiol. Infect. 25(7), 807–817 (2019).Crossref, Medline, CAS, Google Scholar
57. Mullish BH, McDonald JAK, Pechlivanis A et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68(10), 1791–1800 (2019).Crossref, Medline, CAS, Google Scholar
58. Millan B, Park H, Hotte N et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin. Infect. Dis. 62(12), 1479–1486 (2016).Crossref, Medline, CAS, Google Scholar
59. Bilinski J, Grzesiowski P, Sorensen N et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin. Infect. Dis. 65(3), 364–370 (2017).Crossref, Medline, CAS, Google Scholar
60. Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal microbiota transplantation for recurrent clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin. Infect. Dis. 65(10), 1745–1747 (2017).Crossref, Medline, CAS, Google Scholar
61. Huttner BD, de Lastours V, Wassenberg M et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin. Microbiol. Infect. 25(7), 830–838 (2019).Crossref, Medline, CAS, Google Scholar
62. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102(31), 11070–11075 (2005).Crossref, Medline, CAS, Google Scholar
63. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464), 541–546 (2013).Crossref, Medline, Google Scholar
64. Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341(6150), 1241214 (2013).Crossref, Medline, Google Scholar
65. Kootte RS, Levin E, Salojärvi J et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 26(4), 611–619.e6 (2017).Crossref, Medline, CAS, Google Scholar
66. De Groot P, Scheithauer T, Bakker GJ et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 69(3), 502–512 (2020).Crossref, Medline, Google Scholar
67. Allegretti JR, Kassam Z, Mullish BH et al. Effects of fecal microbiota transplantation with oral capsules in obese patients. Clin. Gastroenterol. Hepatol. 18(4), 855–863.e2 (2020).Crossref, Medline, CAS, Google Scholar
68. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2(1), ofv004 (2015).Crossref, Medline, Google Scholar
69. Fischer M, Kao D, Kassam Z et al. Stool donor body mass index does not affect recipient weight after a single fecal microbiota transplantation for Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 16(8), 1351–1353 (2018).Crossref, Medline, Google Scholar
70. Tripathi A, Debelius J, Brenner DA et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15(7), 397–411 (2018).Crossref, Medline, CAS, Google Scholar
71. Bajaj JS, Kassam Z, Fagan A et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66(6), 1727–1738 (2017).Crossref, Medline, CAS, Google Scholar
72. Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology 156(6), 1921–1923.e3 (2019).Crossref, Medline, Google Scholar
73. Bajaj JS, Salzman NH, Acharya C et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a Phase I, randomized, placebo-controlled trial. Hepatology 70(5), 1690–1703 (2019).Crossref, Medline, CAS, Google Scholar
74. McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 30(11), 3658–3668 (2016).Crossref, Medline, CAS, Google Scholar
75. Kang DW, Adams JB, Gregory AC et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5(1), 10 (2017).Crossref, Medline, Google Scholar
76. Kang DW, Adams JB, Coleman DM et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci. Rep. 9(1), 5821 (2019).Crossref, Medline, Google Scholar
77. FDA. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. FDA Guidance Documents (2013). http://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiotaGoogle Scholar
78. Mullish BH, Quraishi MN, Segal JP et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 67(11), 1920–1941 (2018).Crossref, Medline, Google Scholar
79. Keller JJ, Vehreschild MJ, Hvas CL et al. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterol. J. 7(10), 1408–1410 (2019).Crossref, Medline, Google Scholar
80. Australian Government, Department of Health Therapeutic Goods Administration. TGA regulation of faecal microbiota transplant (FMT) products in Australia (2019). http://www.tga.gov.au/tga-regulation-faecal-microbiota-transplant-fmt-products-australiaGoogle Scholar
81. FDA. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. FDA Guidance Documents - Safety & Availability (Biologics) (2019). http://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverseGoogle Scholar

Vol. 15, No. 12

Metrics

Downloaded 129 times

History

Received 17 March 2020

Accepted 22 July 2020

Published online 21 September 2020

Published in print August 2020

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download